Antibacterial activity and clinical evaluation of a new antibiotic, Amikacin were performed.
The results obtained are as follows:
1)
In vitro antibacterial activity: The minimal inhibitory concentration (MIC) of Amikacin was measured by an agar plate dilution method using heart infusion agar (Eiken). Amikacin reveald an excellent, broad spectrum antibacterial activity against 25 standard strains of various bacteria. Amikacin had same antibacterial spectrum like those of other aminoglycoside antibiotics. The MIC of aminoglycoside against 80 strains of coagulase positive Staphylococcus aureus isolated from otorrhoea was distributed over range of 0.39 to 50mcg/ml. with being observed particulary at 3.13mcg/ml. Further, the MIC of Amikacin was 0.39 to 12.5mcg/ml against Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, and 0.78 to 25mcg/ml against 33 strains of Pseudomonas aeruginosa.
2) Stability of Amikacin solution: As to the stability of 10mg/ml, Solution of Amikacin, there was no change in its colour, pH and antibacterial activity when the solution were kept at 5°C and 37°C for 14 days.
3) Results of clinical treatment: When Amikacin was applied locally in 40 cases of the acute or chronic purulent otitis media, it was good in 17 cases, fair in 12 cases, and poor in 11 cases, a rate of effectiveness being 72.5 per cent.
4) Side effect: No side effect was observed when Amikacin was locally used.
抄録全体を表示